findmyKOL

Ganesh Raghu, MD

Enriched profile

Professor, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington; Director, Center for Interstitial Lung Diseases (ILD), UW Medicine · University of Washington Medical Center

ORCIDNPI
Region🇺🇸 Seattle, WA · West · United StatesSpecialtyPulmonary DiseaseFocusInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1990–2009

Ganesh Raghu is Professor, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington; Director, Center for Interstitial Lung Diseases (ILD), UW Medicine at University of Washington Medical Center. OpenAlex indexes 649 publications with 71,831 citations (h-index 112); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Pulmonary Disease profiles in the findmyKOL directory. Clarivate lists Ganesh Raghu as a Highly Cited Researcher (Clinical Medicine, 2019-2022, 2025).

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Ganesh Raghu, MD, is Professor, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington at University of Washington Medical Center, Seattle, WA. The public record shows 649 publications with 71,831 citations (h-index 112), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Sarcoidosis and Beryllium Toxicity Research, Systemic Sclerosis and Related Diseases. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 12 companies, 3 NIH-funded awards (1990–2009).

  • Most recent indexed publication: 2026 · The European respiratory journal
  • Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 12 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Idiopathic Pulmonary Fibrosis7 trialsHypertension1 trialGastroesophageal Cancer1 trialCOPD

Research focus

OpenAlex concept fingerprint
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSarcoidosis and Beryllium Toxicity ResearchSystemic Sclerosis and Related DiseasesChronic Obstructive Pulmonary Disease (COPD) ResearchMedical Imaging and Pathology Studies

Drugs & molecules

across trials, industry payments and publications
Ofevgeneric · NintedanibClinical trialsIndustry payments8Publications4Esbrietgeneric · PirfenidoneClinical trialsIndustry payments2Publications2Tyvasogeneric · TreprostinilClinical trialsIndustry payments9Publications

Works with

trial sponsors and companies reporting payments
Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trialsIndustry payments18United Therapeutics CorporationClinical trialsIndustry payments13Boehringer Ingelheim International GmbHClinical trialsIndustry payments9

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
649publications

Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.

71,831citations

Total citations across indexed works.

112h-index

Hirsch index (OpenAlex). i10-index 330.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
12companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
3NIH grants · 1990–2009

Federally funded research awards.

View funding

Public positions

sourced statements on record
  • Chair

    international committee developing evidence-based guidelines for diagnosis and management of IPF (ATS/ERS/JRS/ALAT)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu
  • Chair

    committee developing clinical practice guidelines on diagnosis of hypersensitivity pneumonitis (ATS/JRS/ALAT)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu
2 more sourced public positions behind the reveal.Reveal →

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    35%
    Corticosteroid30%
    Prednisone100%
    Part D143 patients
    Proton pump inhibitor3.9%
    Omeprazole56%Pantoprazole Sodium44%
    Part D<11 patients
  • Cancer & immunology

    28.6%
    Kinase inhibitor16%
    Ofev100%
    Part D32 patients
    Pyridone6.1%
    Pirfenidone100%
    Part D13 patients
  • Respiratory

    12.3%
    Corticosteroid5.3%
    Dulera75%Qvar Redihaler25%
    Part D<11 patients
    beta2-Adrenergic Agonist4.5%
    Albuterol Sulfate Hfa100%
    Part D24 patients
6 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

3 NIH research awards on record, funded 19902009 per NIH RePORTER. The latest:

13 more award records behind the reveal.Reveal →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Luca Richeldi84Fernando J. Martínez75Kevin R. Flaherty51

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/scientific-contributions/Ganesh-Raghu-38883043

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    ganeshraghuconnection.wordpress.com/meet-the-team

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ganeshraghuconnection.wordpress.com
  • Other

    consultant360.com/podcast/pulmonology/ats/ganesh-raghu-md-whether-ipf-distinct-clinical-entity

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →consultant360.com
  • Other

    pulmonaryfibrosis.org/about-us/who-we-are/medical-advisory-committees/medical-advisory-board

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmonaryfibrosis.org
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Mysore Medical College, University of Mysore, India

    1973
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pulmccsm.uw.edu
  • Board certified

    Internal Medicine and Critical Care Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pulmccsm.uw.edu

Editorial & leadership roles

journal and society appointments
  • Founder

    first pulmonary fibrosis support group in the Pacific Northwest

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu
  • Director

    Interstitial Lung Disease/Sarcoid/Pulmonary Fibrosis Program, UW Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu
  • Co-Director

    Scleroderma Clinic, UW Medicine-Montlake

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    20192020202120222025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Adjunct Professor

    Department of Laboratory Medicine and Pathology, University of Washington

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu
  • Scientific Advisory Board member

    Pulmonary Fibrosis Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmccsm.uw.edu

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.